Quanta Pharma Tirzepatide 60mg + Free BW
Original price was: €188.03.€185.00Current price is: €185.00.
Quanta Pharma Tirzepatide 60mg is a dual agonist peptide that activates both the GLP-1 and GIP receptors. It enhances insulin secretion and decreases glucagon levels, leading to improved glycemic control and weight loss. Lab verified 99.90% purity.
| Quantity | Discount | Price | You save |
|---|---|---|---|
| 3, 4 | 5% off | €178.63 | €9.40 |
| 5, 9 | 10% off | €169.23 | €18.80 |
| 10, 19 | 15% off | €159.83 | €28.20 |
| 20+ Best value | 20% off | €150.42 | €37.61 |
Buy Quanta Pharma Tirzepatide 60mg + Free BW – The Ped Shop Europe
Quanta Pharma Tirzepatide 60mg is a dual agonist peptide that activates both the GLP-1 and GIP receptors. It enhances insulin secretion and decreases glucagon levels, leading to improved glycemic control and weight loss. Lab verified 99.90% purity.
Independently Lab Verified
One new finished product test plus an independent blind screen
Quanta Tirzepatide 60mg is a pharmaceutical-grade dual agonist peptide that activates both GLP-1 and GIP receptors. This lyophilized vial from Quanta Pharma offers researchers a high-purity compound for advanced studies in glycemic control, weight management, and metabolic health. Independently lab-verified across two laboratories, most recently by Analiza Białek at 99% purity and 61.53mg content. Available for Europe delivery with fast dispatch.
Quanta Pharma Tirzepatide 60mg + Free BW Specifications
Research Benefits
- ✓Dual receptor action – Targets both GLP-1 and GIP receptors for comprehensive metabolic research
- ✓Glycemic control – Researched for enhancing insulin secretion and decreasing glucagon levels
- ✓Appetite regulation – Shows significant effects on hunger signalling and satiety pathways
- ✓Weight management – Investigated for substantial effects on body composition and weight loss
- ✓Extended half-life – Approximately 5 days allows for weekly administration in research protocols
How Tirzepatide Works
Tirzepatide is a dual agonist peptide that activates two key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action approach enhances insulin secretion while decreasing glucagon levels.
By targeting both GLP-1 and GIP pathways simultaneously, Tirzepatide research has demonstrated significant potential for improved glycemic control and weight management. The extended half-life of approximately 5 days makes it particularly suitable for once-weekly research protocols.
Tirzepatide vs Semaglutide
While Semaglutide targets only the GLP-1 receptor, Tirzepatide activates both GLP-1 and GIP receptors for a dual-action approach. Research suggests this may offer enhanced effects in metabolic studies, making Tirzepatide a leading compound for laboratory investigation into obesity, type 2 diabetes, and metabolic syndrome.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification: – For use by qualified research personnel only – Keep detailed records of usage and storage as per European research regulations
Legal Notice: This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant European regulations concerning research chemicals.
| Goal Type |
Cut Fat / Lean Out ,Recomp / Body Recomposition |
|---|---|
| Brand |
Quanta Pharma |
